Literature DB >> 11389116

Lung concentrations of telithromycin after oral dosing.

O A Khair1, J M Andrews, D Honeybourne, G Jevons, F Vacheron, R Wise.   

Abstract

Concentrations of telithromycin were measured in plasma, bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses. Concentrations were determined using a microbiological assay. There were 20 subjects in the study, allocated to three nominal time periods: 2, 12 and 24 h. Mean concentrations in plasma, BM, ELF and AM for 2, 12 and 24 h were as follows: 2 h, 1.86 mg/L, 3.88 mg/kg, 14.89 mg/L and 69.32 mg/L; 12 h, 0.23 mg/L, 1.41 mg/kg, 3.27 mg/L and 318.1 mg/L; and 24 h, 0.08 mg/L, 0.78 mg/kg, 0.97 mg/L and 161.57 mg/L. These concentrations of telithromycin in BM and ELF exceeded for 24 h the mean MIC90s of the common respiratory pathogens Streptococcus pneumoniae (0.12 mg/L) and Moraxella catarrhalis (0.03 mg/L), as well as the atypical microorganism Mycoplasma pneumoniae (0.001 mg/L), and suggest that telithromycin may be effective for the treatment of community-acquired pneumonia and chronic obstructive pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11389116     DOI: 10.1093/jac/47.6.837

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers.

Authors:  Jun-Ichi Kadota; Yuji Ishimatsu; Tetsuji Iwashita; Yuichi Matsubara; Kazunori Tomono; Masao Tateno; Roza Ishihara; Claudette Muller-Serieys; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila.

Authors:  C Carbon; R Nusrat
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

3.  Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.

Authors:  Rainer Gattringer; Eleonora Urbauer; Friederike Traunmüller; Markus Zeitlinger; Pejman Dehghanyar; Petra Zeleny; Wolfgang Graninger; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 4.  Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Authors:  Sungmin Kiem; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

Review 5.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

Review 6.  Ketolides in the treatment of community-acquired respiratory tract infections: A review.

Authors:  Martin S Lipsky
Journal:  Curr Ther Res Clin Exp       Date:  2005-05

Review 7.  Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.

Authors:  Jun Shi; Guy Montay; Vijay O Bhargava
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 9.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.